1333. Higher Serum Ferritin Level as Prognostic Factor of Staphylococcus aureus Bacteremia
Session: Poster Abstract Session: Clinical Trials
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • 2013IDSA Higher serum ferritin level as prognostic factor of S. aureus bactremia (Poster No.1333 ).pdf (133.9 kB)
  • Background: Ferritin was associated with the severity of illness in critically ill patients. But there was no data about association between ferritin level and clinical outcome of Staphylococcus aureus bacteremia (SAB).

    Methods: To evaluate the effect of serum ferritin level on 30-day treatment failure of SAB, we investigated 349 adult patients with SAB from Jan. 2008 through Dec. 2012 in a medical center, South Korea.

    Results: Among the 349 patients with SAB, the data of serum ferritin at the onset of SAB were available in only 109 patients (31.2%). Of 109 SAB patients, treatment failure within 30 days after the onset of SAB occurred in 41 patients (39.0%). In logistic regression analysis, Pitt bacteremia score > 3 (odds ratio [OR], 5.178; 95% confidence interval [CI], 1.97-13.59), resistance to clindamycin (OR, 3.508; 95% CI, 1.08-8.814), serum ferritin level ≥ 500 ng/mL (OR, 2.987; 95% CI, 1.08-8.20) were independently associated with 30-day treatment failure of SAB.

    Conclusion: This study suggested that higher serum ferritin level was a surrogate of prognostic factor in adult patients with SAB.

    Min-Gyo Kim, MD1, In-Gyu Bae, MD2, Oh-Hyun Cho, MD2 and Sunjoo Kim, MD3, (1)Internal Medicine, Gyeongsang National University Hospital, Jinju-si, South Korea, (2)Department of Infectious Diseases, Gyeongsang National University Hospital, Jinju, South Korea, (3)Laboratory Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea

    Disclosures:

    M. G. Kim, None

    I. G. Bae, None

    O. H. Cho, None

    S. Kim, None

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.